MARKET

SPRY

SPRY

ARS Pharms
NASDAQ
4.025
-0.025
-0.62%
Opening 14:28 10/14 EDT
OPEN
4.010
PREV CLOSE
4.050
HIGH
4.095
LOW
3.920
VOLUME
961.22K
TURNOVER
--
52 WEEK HIGH
13.15
52 WEEK LOW
3.920
MARKET CAP
400.28M
P/E (TTM)
-1.8521
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRY last week (1005-1009)?
Weekly Report · 2d ago
Weekly Report: what happened at SPRY last week (0928-1002)?
Weekly Report · 10/05 10:29
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
Barchart · 10/05 07:45
Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success
Seeking Alpha · 09/30 14:13
Weekly Report: what happened at SPRY last week (0921-0925)?
Weekly Report · 09/28 10:24
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
PR Newswire · 09/28 08:11
Weekly Report: what happened at SPRY last week (0914-0918)?
Weekly Report · 09/21 10:24
10 small-cap U.S. healthcare stocks with the weakest momentum grades
Seeking Alpha · 09/18 14:20
More
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.

Webull offers ARS Pharmaceuticals Inc stock information, including NASDAQ: SPRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRY stock methods without spending real money on the virtual paper trading platform.